Sanofi (NASDAQ:SNY) Shares Purchased by Boothbay Fund Management LLC

Boothbay Fund Management LLC raised its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 103.6% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 393,814 shares of the company's stock after purchasing an additional 200,346 shares during the quarter. Sanofi accounts for 0.5% of Boothbay Fund Management LLC's portfolio, making the stock its 26th largest position. Boothbay Fund Management LLC's holdings in Sanofi were worth $18,994,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Synergy Asset Management LLC purchased a new position in Sanofi during the 4th quarter worth approximately $25,000. McClarren Financial Advisors Inc. raised its holdings in shares of Sanofi by 952.6% during the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock worth $28,000 after purchasing an additional 543 shares during the last quarter. Bessemer Group Inc. lifted its position in Sanofi by 59.8% during the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company's stock valued at $32,000 after purchasing an additional 242 shares during the period. Lee Danner & Bass Inc. purchased a new stake in Sanofi in the fourth quarter valued at $31,000. Finally, Sierra Ocean LLC acquired a new stake in Sanofi during the 4th quarter worth about $44,000. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Price Performance

SNY stock traded up $1.23 during trading on Wednesday, hitting $54.95. The stock had a trading volume of 1,687,068 shares, compared to its average volume of 1,906,653. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The company's 50-day moving average price is $54.51 and its two-hundred day moving average price is $52.05. The stock has a market capitalization of $138.82 billion, a P/E ratio of 22.07, a PEG ratio of 1.01 and a beta of 0.57. Sanofi has a twelve month low of $52.81 and a twelve month high of $55.21.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its earnings results on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.04. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. The company had revenue of $10.41 billion for the quarter, compared to analysts' expectations of $9.79 billion. During the same quarter in the previous year, the company posted $1.78 EPS. The firm's quarterly revenue was down 11.0% on a year-over-year basis. As a group, research analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Increases Dividend

The firm also recently disclosed an annual dividend, which will be paid on Thursday, June 12th. Investors of record on Friday, May 9th will be paid a dividend of $2.0369 per share. This represents a yield of 3.1%. The ex-dividend date is Friday, May 9th. This is a boost from Sanofi's previous annual dividend of $1.48. Sanofi's dividend payout ratio is currently 57.14%.

Wall Street Analyst Weigh In

SNY has been the topic of a number of recent research reports. Sanford C. Bernstein upgraded Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. BNP Paribas assumed coverage on shares of Sanofi in a research note on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price objective on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. Finally, The Goldman Sachs Group started coverage on shares of Sanofi in a research report on Friday, March 21st. They set a "neutral" rating and a $65.00 price target on the stock. Three research analysts have rated the stock with a hold rating, two have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $63.33.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.